Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.45 -2.0%	$4.94	$2.90 ▼ $11.16	$285.50M	-0.01	2.98 million shs	2.31 million shs
IMUX Immunic	$0.87 -3.3%	$0.84	$0.56 ▼ $2.11	$86.46M	1.39	1.09 million shs	1.06 million shs
PRTC PureTech Health	$17.25 -3.9%	$18.29	$13.30 ▼ $25.00	$431.26M	1.12	1,457 shs	2,313 shs
SANA Sana Biotechnology	$3.00 +1.0%	$3.49	$1.26 ▼ $7.30	$669.67M	1.9	5.83 million shs	8.48 million shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	-1.99%	-4.43%	-27.22%	-38.28%	-37.27%
IMUX Immunic	-3.35%	-6.38%	+8.23%	-13.65%	-25.46%
PRTC PureTech Health	-3.09%	-9.64%	-3.92%	+2.80%	-18.44%
SANA Sana Biotechnology	+1.01%	-23.27%	-25.93%	+65.75%	-36.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	2.3853 of 5 stars	3.4	3.0	1.8	1.7	0.6
IMUX Immunic	2.6825 of 5 stars	3.6	2.0	2.1	2.5	0.6
PRTC PureTech Health	1.8172 of 5 stars	3.8	3.0	0.0	0.0	0.0
SANA Sana Biotechnology	3.2872 of 5 stars	3.5	3.0	3.0	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	2.57	Moderate Buy	$18.20	427.54% Upside
IMUX Immunic	3.29	Buy	$7.50	759.99% Upside
PRTC PureTech Health	3.50	Strong Buy	$45.00	160.87% Upside
SANA Sana Biotechnology	3.00	Buy	$8.00	166.67% Upside

Current Analyst Ratings Breakdown

Latest IMUX, SANA, PRTC, and ALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/10/2025	ALT Altimmune	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
7/10/2025	ALT Altimmune	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$25.00 ➝ $15.00
7/3/2025	SANA Sana Biotechnology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
6/27/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/27/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
6/25/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/24/2025	SANA Sana Biotechnology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
6/5/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $10.00
5/23/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $5.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	13,991.48	N/A	N/A	$1.74 per share	1.98
IMUX Immunic	N/A	N/A	N/A	N/A	$0.20 per share	N/A
PRTC PureTech Health	$4.83M	85.79	$2.29 per share	7.53	$17.04 per share	1.01
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.12 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$95.06M	-$1.26	N/A	N/A	N/A	-451,200.00%	-65.44%	-58.43%	8/12/2025 (Estimated)
IMUX Immunic	-$100.51M	-$1.23	N/A	N/A	N/A	N/A	-562.00%	-242.19%	N/A
PRTC PureTech Health	$27.78M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/26/2025 (Estimated)
SANA Sana Biotechnology	-$266.76M	-$0.88	N/A	N/A	N/A	N/A	-86.58%	-44.49%	8/14/2025 (Estimated)

Latest IMUX, SANA, PRTC, and ALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	SANA Sana Biotechnology	-$0.20	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ALT Altimmune	-$0.3006	N/A	N/A	N/A	$0.00 million	N/A
8/7/2025	Q2 2025	IMUX Immunic	-$0.18	-$0.20	-$0.02	-$0.20	N/A	N/A
5/15/2025	Q1 2025	IMUX Immunic	-$0.25	-$0.25	N/A	-$0.25	N/A	N/A
5/13/2025	Q1 2025	ALT Altimmune	-$0.35	-$0.26	+$0.09	-$0.26	$0.00 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	15.85	15.85
IMUX Immunic	N/A	0.74	0.74
PRTC PureTech Health	N/A	9.33	9.33
SANA Sana Biotechnology	N/A	3.40	3.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
IMUX Immunic	51.82%
PRTC PureTech Health	0.04%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
IMUX Immunic	4.60%
PRTC PureTech Health	5.30%
SANA Sana Biotechnology	30.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	81.11 million	77.78 million	Optionable
IMUX Immunic	70	95.82 million	91.41 million	Optionable
PRTC PureTech Health	100	24.02 million	22.75 million	Not Optionable
SANA Sana Biotechnology	380	225.48 million	157.61 million	Optionable

IMUX, SANA, PRTC, and ALT Headlines

Recent News About These Companies

Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued

August 8 at 4:06 PM | seekingalpha.com

Sana Biotechnology (NASDAQ:SANA) Shares Gap Down - Here's What Happened

August 8 at 1:27 PM | marketbeat.com

Seattle biotech firm Sana Biotechnology raising $75 million through public offering

August 8 at 8:04 AM | bizjournals.com

Sana Biotechnology stock tumbles after pricing public offering

August 7 at 10:45 PM | investing.com

Sana Biotechnology 20.9M share Spot Secondary priced at $3.35

August 7 at 10:45 PM | msn.com

Sana Biotechnology Shares Tumble on Pricing of Public Offering

August 7 at 10:45 PM | marketwatch.com

Sana Biotechnology (SANA) Projected to Post Earnings on Thursday

August 7 at 2:46 AM | marketbeat.com

Sana Biotechnology Announces Pricing of Public Offering

August 6 at 11:24 PM | globenewswire.com

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

August 6 at 4:46 PM | tmcnet.com

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

August 6 at 4:38 PM | globenewswire.com

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 6 at 7:00 AM | globenewswire.com

Novel T1D Therapy Opens the Door to Cell Transplants Sans Immunosuppressants

August 6 at 2:34 AM | msn.com

Sana Biotechnology (NASDAQ:SANA) Trading Up 8.8% - Time to Buy?

August 5, 2025 | marketbeat.com

TD Asset Management Inc Cuts Stock Position in Sana Biotechnology, Inc. (NASDAQ:SANA)

August 5, 2025 | marketbeat.com

Sana Biotechnology's HIP-Modified Pancreatic Islet Cells Show Promising Results in Type 1 Diabetes Study Without Immunosuppression

August 4, 2025 | quiverquant.comQ

Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes

August 4, 2025 | globenewswire.com

Sana Biotechnology (SANA) Rated ‘Market Perform’ on Diabetes Program Prospects

August 1, 2025 | insidermonkey.com

Sana Biotechnology (SANA) Rated ‘Market Perform’ on Diabetes Program Prospects

August 1, 2025 | finance.yahoo.com

Citi Remains Bullish on Sana Biotechnology (SANA)

August 1, 2025 | msn.com

Sana Biotechnology (NASDAQ:SANA) Trading Down 6.7% - Should You Sell?

July 30, 2025 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Purchased by Skandinaviska Enskilda Banken AB publ

July 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUX, SANA, PRTC, and ALT Company Descriptions

Altimmune NASDAQ:ALT

$3.45 -0.07 (-1.99%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$3.47 +0.02 (+0.58%)

As of 08/8/2025 07:59 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Immunic NASDAQ:IMUX

$0.87 -0.03 (-3.35%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$0.88 +0.01 (+1.36%)

As of 08/8/2025 07:58 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

PureTech Health NASDAQ:PRTC

$17.39 -0.56 (-3.12%)

As of 08/8/2025 03:58 PM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Sana Biotechnology NASDAQ:SANA

$3.00 +0.03 (+1.01%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$3.01 +0.01 (+0.33%)

As of 08/8/2025 07:58 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time